Key result
The Philips Minicare cTnI point-of-care immunoassay demonstrated a limit of quantitation of 38 ng/L and a 99th percentile upper reference limit of 43 ng/L, correlating well with standard assays.
Why the study?
Does the Philips Minicare cTnI point-of-care immunoassay demonstrate adequate analytical performance for measuring cardiac troponin I compared to standard laboratory assays?
Population
750 healthy adults, aged 18 to 86 years, and clinical samples from 4 different hospitals
Comparison
Philips Minicare cTnI point-of-care immunoassay vs Beckman Coulter Access, AccuTnI+3
Design
Other
Authors
Loading...
Supports POC cTnI testing for faster AMI evaluation; leaves open clinical outcome validation before adoption.
Observational (n=750)
Yes
Does the Philips Minicare cTnI point-of-care immunoassay demonstrate adequate analytical performance for measuring cardiac troponin I compared to standard laboratory assays?
The Philips Minicare cTnI point-of-care assay demonstrates sensitive and precise analytical performance suitable for near-patient clinical use in diagnosing acute myocardial infarction.
Kemper et al. (2016) conducted an observational in Healthy adults (n=750). Philips Minicare cTnI point-of-care immunoassay vs. Beckman Coulter Access, AccuTnI+3 was evaluated on Analytical performance including limit of quantitation and 99th percentile upper reference limit. The Philips Minicare cTnI point-of-care immunoassay demonstrated a limit of quantitation of 38 ng/L and a 99th percentile upper reference limit of 43 ng/L, correlating well with standard assays.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: